Blog
RSS FeedPosted by Michael Wonder on 03 Jan 2017
2016 in review
4 January 2017 - The PBAC considered 192 submissions in 2016; 193 were considered by the Committee in 2015. ...
Posted by Michael Wonder on 03 Jan 2017
Amicus Therapeutics set for share of Fabry market after NICE approval
3 January 2017 - England and Wales’ cost effectiveness watchdog NICE has given a final recommendation to a new treatment ...
Posted by Michael Wonder on 03 Jan 2017
The NICE year in review
3 January 2017 - NICE has reflected on some of the news over the past twelve months. ...
Posted by Michael Wonder on 03 Jan 2017
'Morally bankrupt': Government stalls funding for life-saving cystic fibrosis drug for children
3 January 2017 - Little Anna dances around her room, stealing hearts with playful pouts that break into cheeky grins. ...
Posted by Michael Wonder on 03 Jan 2017
NICE says liver cancer treatment to stay within the Cancer Drugs Fund, but not recommended for routine NHS use
30 December 2016 - The drug, sorafenib tosylate (Nexavar), which is used for treating advanced hepatocellular carcinoma, is not value for ...
Posted by Michael Wonder on 02 Jan 2017
Coalition to simplify private health policies
2 January 2016 - The Turnbull government will consider a plan to streamline thousands of private health insurance policies into ...
Posted by Michael Wonder on 02 Jan 2017
Radical plan for bigger Medicare rebates in the bush
3 January 2017 - Health fund members in regional and remote areas would be given larger Medicare payments or more ...
Posted by Michael Wonder on 02 Jan 2017
Bronchial carcinoma: additional use of crizotinib not seen
2 January 2017 - The dossier does not contain any suitable data for patients with ROS1 positive non-small-cell lung cancer. ...
Posted by Michael Wonder on 01 Jan 2017
New Zealand Pharmaceutical Schedule - 1 January 2017
1 January 2017 - The January 2017 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Dec 2016
Schedule of Pharmaceutical Benefits - 1 January 2017 update
1 January 2017 - The 1 January 2017 issue of the Schedule of Pharmaceutical Benefits sees a number of new ...
Posted by Michael Wonder on 31 Dec 2016
Breast cancer drug rejected for NHS use on cost-benefit grounds
29 December 2016 - Charities angered by guidance on Kadcyla, which costs £90,000 per year per patient and gives extra nine ...
Posted by Michael Wonder on 30 Dec 2016
AstraZeneca chief says NHS drug approval process hurts patients
29 December 2016 - Protracted negotiations deny access to life-saving treatments, says Pascal Soriot. ...
Posted by Michael Wonder on 23 Dec 2016
‘Wonder’ drug for sufferers given green light for NHS use
22 December 2016 - The decision means 6,890 people in England and Wales who suffer with the debilitating inflammatory disease ...
Posted by Michael Wonder on 21 Dec 2016
Summary of the agenda for the PBAC March 2017 meeting
22 December 2016 - The PBAC will consider 40 submissions (23 major & 17 minor) at its next scheduled meeting ...
Posted by Michael Wonder on 21 Dec 2016
Manual of resource items and their associated unit costs
21 December 2016 - The PBAC has endorsed version 5.0 of the Manual of resource items and their associated unit ...